科济药业-B(02171)今日盘中大涨5.05%,引发市场关注。
这一涨幅或与公司自主研发的新药临床进展有关。公司自研产品KJC2219已在中国启动针对B细胞淋巴瘤的临床试验。此外,公司关键II期临床试验CT041-ST-01也取得了阳性结果,这是一种用于晚期胃癌治疗的CAR-T细胞疗法。这些积极进展增强了市场对公司药物管线的信心,推动股价上涨。
科济药业是一家总部位于香港的生物技术公司,专注于开发创新免疫细胞疗法和靶向肿瘤治疗药物。公司在研产品线丰富,若持续获得临床进展利好,有望为公司创收增长注入新动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.